PubMed· 2014· Review
Corneal collagen crosslinking: a systematic review.
- 1,798citations
- 2014year
Short summary
Corneal crosslinking (CXL) effectively arrests the progression of keratoconus (KCN), post-LASIK ectasia (PLE), and pellucid marginal degeneration (PMD) by increasing corneal stiffness through riboflavin and UVA radiation.
AI-generated from the title and abstract; the full text is not read.
Key points
- CXL increases corneal stiffness by inducing stromal crosslinks via riboflavin and UVA radiation.
- CXL is an established treatment to arrest the progression of keratoconus (KCN).
- CXL is also effective for post-LASIK ectasia (PLE) and pellucid marginal degeneration (PMD).
- The procedure shows efficacy in treating corneal infections, chemical burns, and bullous keratopathy.
AI-generated from the title and abstract; the full text is not read.
Abstract
Keratoconus (KCN) is an ectatic disorder with progressive corneal thinning and a clinical picture of corneal protrusion, progressive irregular astigmatism, corneal fibrosis and visual deterioration. Other ectatic corneal disorders include: post-LASIK ectasia (PLE) and pellucid marginal degeneration (PMD). Corneal crosslinking (CXL) is a procedure whereby riboflavin sensitization with ultraviolet A radiation induces stromal crosslinks. This alters corneal biomechanics, causing an increase in corneal stiffness. In recent years, CXL has been an established treatment for the arrest of KCN, PLE and PMD progression. CXL has also been shown to be effective in the treatment of corneal infections, chemical burns, bullous keratopathy and other forms of corneal edema. This is a current review of CXL - its biomechanical principles, the evolution of CXL protocols in the past, present and future, indications for treatment, treatment efficacy and safety.
The authors' abstract, as published at the source. PubMed, 2014 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Radiology, Nuclear Medicine and Imaging
Radiology, Nuclear Medicine and ImagingMedicine